No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Autor: Castaño-Bonilla, Tamara, Barragán, Eva, Sargas, Claudia, Sanz, Alejandro, Algarra, Lorenzo, Herrera-Puente, Pilar, García-Boyero, Raimundo, Barrios, Manuel, Martinez-Cuadron, David, Rodriguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Serrano-López, Josefina, Martínez-López, Joaquín, Sayas-Lloris, María José, Olave, María Teresa, Riaza-Grau, Rosalía, Castillo, Teresa Bernal-Del, Larrayoz, María José, Amigo, Raquel

Publikováno v: Disease Markers; 8/23/2022, p1-9, 9p

Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy^*.

Autor: Miyamoto, Toshihiro, Sanford, David, Tomuleasa, Ciprian, Hsiao, Hui-Hua, Olivera, Leonardo José Enciso, Enjeti, Anoop Kumar, Gimenez Conca, Alberto, Castillo, Teresa Bernal del, Girshova, Larisa, Martelli, Maria Paola, Guvenc, Birol, Delgado, Alexander, Duan, Yinghui, Garbayo Guijarro, Belen, Llamas, Cynthia, Lee, Je-Hwan

Publikováno v: Leukemia & Lymphoma; Apr2022, Vol. 63 Issue 4, p928-938, 11p

Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy^*.

Autor: Miyamoto, Toshihiro¹ (AUTHOR), Sanford, David² (AUTHOR), Tomuleasa, Ciprian³ (AUTHOR), Hsiao, Hui-Hua⁴ (AUTHOR), Olivera, Leonardo José Enciso⁵ (AUTHOR), Enjeti, Anoop Kumar⁶ (AUTHOR), Gimenez Conca, Alberto⁷ (AUTHOR), Castillo, Teresa Bernal del⁸ (AUTHOR), Girshova, Larisa⁹ (AUTHOR), Martelli, Maria Paola¹⁰ (AUTHOR), Guvenc, Birol¹¹ (AUTHOR), Delgado, Alexander¹² (AUTHOR), Duan, Yinghui¹³ (AUTHOR), Garbayo Guijarro, Belen¹⁴ (AUTHOR), Llamas, Cynthia¹³ (AUTHOR), Lee, Je-Hwan¹⁵ (AUTHOR)

Publikováno v: Leukemia & Lymphoma. Apr2022, Vol. 63 Issue 4, p928-938. 11p.

Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy ^.

Autor: Miyamoto T; Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan., Sanford D; Leukemia/Bone Marrow Transplant Program of BC, Division of Hematology, The University of British Columbia, Vancouver, BC, Canada., Tomuleasa C; Department of Hematology - Medfuture Research Center for Advanced Medicine, Ion Chiricuta Clinical Cancer Center, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Hsiao HH; Department of Internal Medicine, Division of Hematology-Oncology, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan., Olivera LJE; Instituto Nacional de Cancerología, Bogotá, Colombia., Enjeti AK; Calvary Mater Newcastle, University of Newcastle and New South Wales Health Pathology, Waratah, Australia., Gimenez Conca A; Section of Hematology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Castillo TBD; Servicio de Hematología y Hemoterapia, University Hospital Central de Asturias, ISPA, IUOPA, Oviedo, Spain., Girshova L; Federal State Budgetary Institution 'Almazov National Medical Research Centre' of the Ministry of Health of the Russian Federation, St. Petersburg, Russia., Martelli MP; Department of Medicine and Surgery - Section of Hematology and Clinical Immunology, Perugia University, 'Santa Maria della Misericordia' Hospital, Perugia, Italy., Guvenc B; Department of Hematology, Faculty of Medicine, Cukurova University, Adana, Turkey., Delgado A; AbbVie, Inc., Singapore, Singapore., Duan Y; AbbVie, Inc., North Chicago, IL, USA., Garbayo Guijarro B; AbbVie, Inc., Madrid, Spain., Llamas C; AbbVie, Inc., North Chicago, IL, USA., Lee JH; Department of Hematology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2022 Apr; Vol. 63 (4), pp. 928-938. Date of Electronic Publication: 2022 Feb 11.